Form 8-K TherapeuticsMD, Inc. For: May 06

Go back to Form 8-K TherapeuticsMD, Inc. For: May 06

TherapeuticsMD (TXMD) PT Lowered to $5 at Stifel

May 6, 2021 2:00 PM EDT

Stifel analyst Annabel Samimy lowered the price target on TherapeuticsMD (NASDAQ: TXMD) to $5.00 (from $6.00) while maintaining a Buy rating.

The analyst commented, "While investor worry remained at a peak, TXMD posted sales of $19.9mn/Cons $19,8mn, with FDA-product sales of $18.3mn coming... More